Company intelligence / Profile preview

Acusphere, Inc.

Watertown, Massachusetts, United Statesacusphere.com ↗
Ownership
Private
Development stage
Other
01

Overview

Acusphere developed Imagify™—an injectable suspension of perflubutane polymer microspheres—for non-invasive detection of coronary artery disease. The company submitted an NDA to the FDA in April/June of 2008 but received a complete response letter in February of the following year requiring additional clinical trials before approval. A Marketing Authorization Application was also submitted to the EMA for European review. Other assets include AI‑525 and AI‑850 (sold to Cephalon), and AI‑128 for asthma developed with Elan. The company’s proprietary technology enables reformulation and sustained release of hydrophobic drugs.[2][6]

Therapeutic areas
OncologyPulmonologyCardiovascularNeurology
Modalities
Injectable suspensions (microspheres)[1][5]Reformulated hydrophobic drugs[1]
Industry
Biotech
02

Drug pipeline

2 assets

AI-850

Unknown

1 more asset in the full pipeline.

03

Partnerships

Elan Pharmaceuticals ($7.5M contribution on AI‑128/asthma)Cephalon acquired two programs ($31M total)ongoing regulatory discussions with FDA/EMA.[1]

Beyond the preview

Go deeper on Acusphere, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acusphere, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call